Keeping Up With CAR-T

FOR CELL THERAPY AND SOLID ORGAN TRANSPLANT CENTERS

CAR-T (T-cells expressing Chimeric Antigen Receptors) therapy has displayed significant success in treating patients with otherwise incurable B-cell lymphomas. Based on the promise generated from these successes, the field is rapidly expanding to include new disease indications and CAR designs. CAR-T adoption, however, is not without challenges. The industry needs to learn as quickly as possible about all aspects of CAR-T.

The Center for Blood and Marrow Transplant Research (CIBMTR) has expanded to capture CAR-T data for research purposes. Six new CAR-T forms have been created. In addition, six forms originally created for HCT have been modified to include CAR-T data. CIBMTR supports the electronic submission of 10 of these 12 forms (via its AGNIS interface).

COMPLETE THE FORM BELOW TO READ MORE.  Learn what is needed to keep up with CAR-T – now and in the near future. 

    First Name (Required)

    Last Name (Required)

    Office Phone

    Cell Phone

    Area of Interest

    BMTCAR-TSolid OrganLABHero

    Hospital Name (Required)

    E-mail (Required)

    Let’s Talk!

    Would you like to talk to an EDITLife team member? Or send an email? Either way, we look forward to hearing from you!

    Ed Smith, Director, Business Development

    412-924-3415

    ESmith@msa.com

    By submitting this request, you agree to be added to MSA’s email list. We won’t share your email address with anyone and we won’t ever send you SPAM (per our Privacy Policy)